Stryker Corporation (SYK)
NYSEHealth CareMedical - DevicesSnapshot 2026-11-05
$335.08-1.35%
Close 2026-11-05 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-11-05
QuarterlyIQ Insights · SYK
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-11-05.
The screen ranks SYK against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 4 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 42% for the rest of the cohort, n=10089).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
1 2026 Outlook We are updating our full year 2026 guidance and now expect organic net sales growth (2) in the range of 6.5% to 7.0% and adjusted net earnings per diluted share (2) to be in the range…
Stated in 7 of 8 supplied quarters. Management reported: “1 2026 Outlook We are updating our full year 2026 guidance and now expect organic net sales growth (2) in the range of 6.5% to 7.0% and adjusted net earnings per diluted share (2) to be in the range of $14.80 to $14.90.” “2026 Outlook We are narrowing our full year 2026 guidance and now expect organic net sales growth (2) in the range of 8.3% to 9.3% and adjusted net earnings per diluted share (2) in the range of $14.95 to $15.10.” Revenue was $6.520 billion in 2026-Q3.
“1 2026 Outlook We are updating our full year 2026 guidance and now expect organic net sales growth (2) in the range of 6.5% to 7.0% and adjusted net earnings per diluted share (2) to be in the range…”
“2026 Outlook We are narrowing our full year 2026 guidance and now expect organic net sales growth (2) in the range of 8.3% to 9.3% and adjusted net earnings per diluted share (2) in the range of $14.…”
“2026 Outlook We are maintaining our full year 2026 guidance of organic net sales growth (2) in the range of 8.0% to 9.5% and adjusted net earnings per diluted share (2) in the range of $14.90 to $15.…”
“1 2026 Outlook Based on our momentum exiting 2025, healthy procedural volumes and strong demand for our capital products, we expect 2026 organic net sales growth (2) to be in the range of 8.0% to 9.5…”
“2025 Outlook Based on our sales momentum, sustained demand for our products and commitment to margin expansion, we are raising our full year 2025 guidance and now expect organic net sales growth (2)…”
“2025 Outlook Considering our year-to-date results, strong demand for our products and our operational momentum, we are raising our full year 2025 guidance and now expect organic net sales growth (2)…”
1 2026 Outlook We are updating our full year 2026 guidance and now expect organic net sales growth (2) in the range of 6.5% to 7.0% and adjusted net earnings per diluted share (2) to be in the range…
Stated in 7 of 8 supplied quarters. Management reported: “1 2026 Outlook We are updating our full year 2026 guidance and now expect organic net sales growth (2) in the range of 6.5% to 7.0% and adjusted net earnings per diluted share (2) to be in the range of $14.80 to $14.90.” “2026 Outlook We are narrowing our full year 2026 guidance and now expect organic net sales growth (2) in the range of 8.3% to 9.3% and adjusted net earnings per diluted share (2) in the range of $14.95 to $15.10.”
2025 Outlook Based on our sales momentum, sustained demand for our products and commitment to margin expansion, we are raising our full year 2025 guidance and now expect organic net sales growth (2)…
Stated in 2 of 8 supplied quarters. Management reported: “2025 Outlook Based on our sales momentum, sustained demand for our products and commitment to margin expansion, we are raising our full year 2025 guidance and now expect organic net sales growth (2) of 9.8% to 10.2% and adjusted net earnings per diluted share (2) to be in the range of $13.50 to $13.60.” “2025 Outlook Considering our year-to-date results, strong demand for our products and our operational momentum, we are raising our full year 2025 guidance and now expect organic net sales growth (2) of 9.5% to 10.0% and adjusted net earnings per diluted share (2) to be in the range of $13.40 to $13.60.” Operating income was $1.659 billion in 2026-Q2.
Restore operations and customer service following the cybersecurity incident reported in March 2026.
Continue the share repurchase program, with timing and amounts determined by management.
Over the trailing year it converted 0.77x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 52% of the time over the next year (vs 44% for the rest of the cohort, n=3371).
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
16 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 46% of the time over the next year (vs 44% for the rest of the cohort, n=13229).
Not investment advice. As of 2026-11-05.
“2025 Outlook Considering our first quarter results, strong demand for our capital products and our commercial momentum in the end markets in which we operate, we are raising our full year 2025 organi…”
“1 2026 Outlook We are updating our full year 2026 guidance and now expect organic net sales growth (2) in the range of 6.5% to 7.0% and adjusted net earnings per diluted share (2) to be in the range…”
“2026 Outlook We are narrowing our full year 2026 guidance and now expect organic net sales growth (2) in the range of 8.3% to 9.3% and adjusted net earnings per diluted share (2) in the range of $14.…”
“2026 Outlook We are maintaining our full year 2026 guidance of organic net sales growth (2) in the range of 8.0% to 9.5% and adjusted net earnings per diluted share (2) in the range of $14.90 to $15.…”
“1 2026 Outlook Based on our momentum exiting 2025, healthy procedural volumes and strong demand for our capital products, we expect 2026 organic net sales growth (2) to be in the range of 8.0% to 9.5…”
“2025 Outlook Based on our sales momentum, sustained demand for our products and commitment to margin expansion, we are raising our full year 2025 guidance and now expect organic net sales growth (2)…”
“2025 Outlook Considering our year-to-date results, strong demand for our products and our operational momentum, we are raising our full year 2025 guidance and now expect organic net sales growth (2)…”
“We expect our adjusted net earnings per diluted share (2) to be the range of $13.20 to $13.45.”
“2025 Outlook Based on our sales momentum, sustained demand for our products and commitment to margin expansion, we are raising our full year 2025 guidance and now expect organic net sales growth (2)…”
“2025 Outlook Considering our year-to-date results, strong demand for our products and our operational momentum, we are raising our full year 2025 guidance and now expect organic net sales growth (2)…”